Aislinn Antrim, Associate Editorial Director

Practical insights for navigating rare, high-stakes toxicities.

Expert insights on toxicity management, resistance mechanisms, and frontline integration of Bruton tyrosine kinase inhibitors in MCL.

New data, emerging targets, and evolving ADC use are reshaping second-line decisions.

Matthew Warrick, PharmD, BCPS, BCOP, discusses mechanisms, safety nuances, and practical considerations shaping bispecific antibody use in lymphoma care.

Key risks, overlooked toxicities, and real-world monitoring strategies for bispecific T-cell engagers.

Oncology pharmacist Emma Jones, PharmD, BCOP, outlines how clinicians can recognize and manage these complex cases.

A dual-center retrospective study compares 2 fludarabine washout strategies to assess their impact on neutrophil engraftment, infections, growth factor use, and hospital length of stay.

Disha Patel, PharmD, discusses current data on G-CSF use during HiDAC consolidation for AML, addressing relapse concerns, infection risk, clinical decision-making, and why practice patterns remain divided across institutions.

From bispecifics to real-world evidence, Amy Seung previews the science, community, and advocacy opportunities defining this year's meeting.

The acquisition brings an autoinjector platform and a broad device portfolio into emmbecta's growing chronic care ecosystem.

FDA approves secukinumab for adolescents 12 years and older with moderate to severe hidradenitis suppurativa, offering the first IL-17A option and new hope for earlier relief.

No FDA-approved oral suspension of valacyclovir currently exists, meaning pharmacies must continue relying on compounded preparations for patients unable to swallow tablets while Hyloris works to resolve the manufacturing issues.

FDA priority review of rusfertide signals a new PV option, cutting phlebotomy reliance and improving hematocrit control, with pharmacists guiding injections and safety.

The platform offers uninsured patients discounted drug prices, though it is important to note that the platform does not sell drugs, and only a small number are currently available.

In this episode, we break down the genetics, diagnosis, and clinical impact of HCM, explore how management strategies have evolved, and discuss the emerging role of cardiac myosin inhibitors in treating obstructive disease.

Morgan McSweeney, PhD, discusses why current US advisory structures are vulnerable to political influence, the vital role pharmacists play in sustaining vaccine confidence, and why universal hepatitis B vaccination remains essential in the US.

Morgan McSweeney, PhD, discusses the evidence behind the hepatitis B vaccine’s safety, how pharmacists can communicate with concerned parents, and the impact of shifting federal guidance on vaccine confidence.

The FDA approved mitapivat, the first oral therapy for thalassemia due to anemia, offering hope for patients with transfusion-dependent and non–transfusion-dependent forms.

The FDA approves Accrufer for children 10 and older, offering a well-tolerated solution for iron deficiency, enhancing pediatric health outcomes.

FDA approves Rybrevant Faspro, a groundbreaking subcutaneous therapy for EGFR-mutated lung cancer, enhancing patient comfort and survival rates.

Host Craig Beavers sits down with Marc Baines, cofounder and executive director of the HeartLife Foundation, to explore heart failure care through the lens of lived experience.

The FDA has approved a new combination therapy for BRCA2-mutated metastatic prostate cancer, showing significant efficacy in clinical trials.

As the new chair of the Advisory Committee on Immunization Practices (ACIP) signals interest in revisiting childhood and adolescent vaccine schedules, immunologist Morgan McSweeney, PhD, stresses that any changes must be anchored in decades of rigorous safety and efficacy data.

New research reveals that low cholesterol levels may indicate increased severity in Crohn disease, offering a potential new biomarker for monitoring inflammation.

New long-term data reveal avapritinib's impressive efficacy and safety in advanced systemic mastocytosis.

The Isa-VRd regimen shows consistent efficacy results across all age and frailty levels in patients with newly diagnosed multiple myeloma.